

**Drugs and Therapeutics (D & T) Committee
Meeting Results
June 14, 2017**

Drug Name	Review Type	Committee Recommendation	Prior Approval Status – Final Determination
Soliqua	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Exondys 51	New Drug Initial Review	Coverage decision postponed pending additional clinical trial data.	Coverage decision postponed pending additional clinical trial data.
Ocrevus	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA (approved for primary progressive MS)
Xermelo	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Bevespi Aerosphere	New Drug Initial Review	Preferred remove PA	Preferred remove PA
Utibron	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Spinraza	New Drug Initial Review		Final decision pending.
Dupixent	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Invega Trinza	New Drug Appeal	Preferred with PA	Preferred with PA
Dyanavel XR	New Drug Appeal	Non-preferred requires PA	Non-preferred requires PA
Granix	New Drug Appeal	Preferred remove PA	Preferred remove PA
Pertzye	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Quillichew ER	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Quillivant XR	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Lyrica	PDL Appeal	Non-preferred requires PA	Preferred remove PA